D3 HIV trial completes recruitment ahead of schedule

19 Sep 2023

The D3 trial team is excited to announce that they have finished recruiting trial participants ahead of schedule. 

People living with HIV have to take medicines for life. Therefore, it is important to ensure that these medicines work well and continue to be safe for children and young people living with HIV. New approaches that make these anti-HIV medicines less toxic and easier to take could help improve their quality of life and outcomes. 

D3 is testing whether treating children and young people living with HIV with a new tablet, made up of two antiretroviral drugs, dolutegravir (DTG) and lamivudine (3TC), is as good and effective at treating HIV as the currently recommended treatment, made up of three drugs, including DTG, 3TC and one more antiretroviral drug. 

The trial successfully recruited over 370 children and adolescents, aged two to 15 years, from South Africa, Spain, Thailand, Uganda and the UK. 

D3 is sponsored by Penta and funded by ViiV Healthcare. Enrolment was coordinated by the MRC Clinical Trials Unit at UCL. The rapid rate of recruitment is a testament to the appeal of a DTG/3TC drug and the dedication and commitment of the trial staff in finding better treatment options for children living with HIV. Findings from this study have the potential to improve the lives of children living with HIV by simplifying treatment to one small tablet given once-daily and reducing drug-associated toxicity. 

Further information: